AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns
AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. For example, the AbbVie Inc. (NYSE:ABBV) share price has soared 100% in the last half decade. Most would be very happy with that. And in the last week the share price has popped 4.5%. But this could be related to the buoyant market which is up about 2.8% in a week.
当你购买股票时,总是存在它可能会下跌100%的可能性。但从积极的一面来看,你在一只真正优秀的股票上可以赚得远超过100%。例如,艾伯维公司(纽交所:ABBV)的股价在过去五年间飙升了100%。大多数人对此会非常高兴。而在过去一周内,股价上涨了4.5%。但这可能与市场的上涨有关,市场在一周内上升了约2.8%。
Since it's been a strong week for AbbVie shareholders, let's have a look at trend of the longer term fundamentals.
由于这一周对艾伯维公司的股东来说非常强劲,让我们来看看长期基本面的趋势。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
虽然市场是一个强大的定价机制,但股价反映的却是投资者情绪,而不仅仅是基础业务表现。一种不完美但简单的考虑收入每股收益(EPS)变化与股价变动的市场认知变化的方法是比较它们之间的差异。
Over half a decade, AbbVie managed to grow its earnings per share at 5.7% a year. This EPS growth is slower than the share price growth of 15% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth. This optimism is visible in its fairly high P/E ratio of 62.32.
在过去五年中,艾伯维每年设法将每股收益增长5.7%。这一EPS增长低于同期股价每年15%的增长。这表明市场参与者现在更加看重该公司。这并不令人惊讶,考虑到五年来的盈利增长记录。这种乐观情绪在其较高的市盈率62.32中可见一斑。
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
下图显示了EPS随时间变化的情况(点击图像以显示确切值)。
Dive deeper into AbbVie's key metrics by checking this interactive graph of AbbVie's earnings, revenue and cash flow.
通过查看艾伯维公司的收益、营业收入和现金流的互动图表,深入了解艾伯维公司的关键指标。
What About Dividends?
关于分红派息的问题
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of AbbVie, it has a TSR of 148% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.
除了衡量股价回报外,投资者还应考虑总股东回报(TSR)。TSR考虑了任何剥离或折扣资本筹集的价值,以及任何分红,基于分红被再投资的假设。可以公平地说,TSR为支付分红的股票提供了更全面的概述。以艾伯维公司为例,它在过去5年内的TSR为148%。这超过了我们之前提到的股价回报。公司支付的分红因此提升了总股东回报。
A Different Perspective
不同的视角
AbbVie shareholders gained a total return of 20% during the year. But that was short of the market average. On the bright side, that's still a gain, and it's actually better than the average return of 20% over half a decade This could indicate that the company is winning over new investors, as it pursues its strategy. It's always interesting to track share price performance over the longer term. But to understand AbbVie better, we need to consider many other factors. Even so, be aware that AbbVie is showing 3 warning signs in our investment analysis , you should know about...
艾伯维公司的股东在一年内获得了20%的总回报。但这低于市场平均水平。值得庆幸的是,这仍然是一个增益,实际上比过去五年半的平均回报20%要好。这可能表明公司在赢得新的投资者,正追求其策略。长期跟踪股价表现总是很有趣。但要更好地理解艾伯维,我们需要考虑许多其他因素。即便如此,请注意,艾伯维在我们的投资分析中显示出3个警告信号,你应该了解...
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然,你可能会通过其他地方寻找一个绝佳的投资机会。所以请查看这个我们预计将增长每股收益的公司免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文中引用的市场回报反映了当前在美国交易所上市股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。